- Home
- STEW vs TNGX Comparison
STEW vs TNGX Comparison
Compare STEW & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | STEW | TNGX |
|---|---|---|
| Founded | 1972 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.4B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | STEW | TNGX |
|---|---|---|
| Price | $18.38 | $12.51 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 84.5K | ★ 3.1M |
| Earning Date | 01-01-0001 | 02-26-2026 |
| Dividend Yield | ★ 3.71% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.44 | N/A |
| Revenue | N/A | ★ $66,501,000.00 |
| Revenue This Year | N/A | $52.80 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.34 | ★ N/A |
| Revenue Growth | N/A | ★ 53.29 |
| 52 Week Low | $11.97 | $1.03 |
| 52 Week High | $14.94 | $13.46 |
Technical Indicators
Market Signals| Indicator | STEW | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 57.70 | 62.52 |
| Support Level | $18.05 | $11.69 |
| Resistance Level | $18.41 | $12.96 |
| Average True Range (ATR) | 0.19 | 0.78 |
| MACD | 0.05 | -0.01 |
| Stochastic Oscillator | 90.98 | 81.65 |
Price Performance
Historical ComparisonAbout STEW SRH Total Return Fund Inc.
SRH Total Return Fund, Inc. is a non-diversified closed-end management investment company. The company's investment objective is to seek total returns. Its fund utilizes a bottom-up, value-driven investment process to identify securities of good quality businesses trading below estimated intrinsic value. The Funds are available as an actively-managed closed-end fund, an actively managed ETF and a passively-managed ETF.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.